Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial is a research paper published in medRxiv (2022). On theSindex it has a DataRank of 0.330. It has been cited 4 times, with 4 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0.0889
From 4 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 4 citers.
National Institutes of Health
Grant: 3T32DK072922-08S1
Kidney Disease and Inflammation
National Institutes of Health
Grant: 5TL1DK132771-05
IGNITE KUH NRSA Training Core
National Institutes of Health
Grant: 1KL2TR003016-01
Institutional Career Development Core
National Institutes of Health
Grant: 3UL1TR003015-03S1
The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve Health
National Institutes of Health
Grant: 5T32AI007496-27
Interdisciplinary Training Program in Immunology
National Institutes of Health
Grant: 2R01AI124214-06
Role of Type 2 Immunity in Innate Protection from C. difficile
Fields of Study
Keywords
Sustainable Development Goals